Company profile LTRN
After 38 days of this quarter the interest is at 20.0. Based on that we can calculate that during remaining 53 days it will total up to 48.0. Lantern Pharma stock expected interest is significantly higher compared to same quarter last year (+inf%) but lower than previous quarter (-63.4%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 204 inf% QoQ | 124 -39.2% QoQ | 162 30.6% QoQ |
| 2020 | 167 inf% YoY 3.1% QoQ | 217 6.4% YoY 29.9% QoQ | 23 -81.5% YoY -89.4% QoQ | 64 -60.5% YoY 178.3% QoQ |
| 2021 | 141 -15.6% YoY 120.3% QoQ | 98 -54.8% YoY -30.5% QoQ | 228 891.3% YoY 132.7% QoQ | 89 39.1% YoY -61.0% QoQ |
| 2022 | 29 -79.4% YoY -67.4% QoQ | 149 52.0% YoY 413.8% QoQ | 97 -57.5% YoY -34.9% QoQ | 25 -71.9% YoY -74.2% QoQ |
| 2023 | 0 -100.0% YoY -100.0% QoQ | 73 -51.0% YoY inf% QoQ | 0 -100.0% YoY -100.0% QoQ | 131 424.0% YoY inf% QoQ |
| 2024 | 20 inf% YoY -84.7% QoQ | - | - | - |
The average 5 years interest of Lantern Pharma stock was 7.82 per week. The last year interest of Lantern Pharma stock compared to the last 5 years has changed by -44.88%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -56.46%.
There is not enough data for Lantern Pharma login to provide analysis
There is not enough data for Lantern Pharma login to provide correlation calculation
There is not enough data for Lantern Pharma login to provide analysis
There is not enough data for Lantern Pharma news to provide analysis
There is not enough data for Lantern Pharma news to provide correlation calculation
There is not enough data for Lantern Pharma news to provide analysis
After 34 days of this quarter the interest is at 196.0. Based on that we can calculate that during remaining 58 days it will total up to 530.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 184 |
| 2019 | 718 290.2% QoQ | 569 -20.8% QoQ | 472 -17.0% QoQ | 518 181.5% YoY 9.7% QoQ |
| 2020 | 730 1.7% YoY 40.9% QoQ | 543 -4.6% YoY -25.6% QoQ | 563 19.3% YoY 3.7% QoQ | 467 -9.8% YoY -17.1% QoQ |
| 2021 | 553 -24.2% YoY 18.4% QoQ | 483 -11.0% YoY -12.7% QoQ | 509 -9.6% YoY 5.4% QoQ | 497 6.4% YoY -2.4% QoQ |
| 2022 | 628 13.6% YoY 26.4% QoQ | 539 11.6% YoY -14.2% QoQ | 625 22.8% YoY 16.0% QoQ | 571 14.9% YoY -8.6% QoQ |
| 2023 | 657 4.6% YoY 15.1% QoQ | 423 -21.5% YoY -35.6% QoQ | 643 2.9% YoY 52.0% QoQ | 196 -65.7% YoY -69.5% QoQ |
The average 5 years interest of biotechnology companies was 42.65 per week. The last year interest of biotechnology companies compared to the last 5 years has changed by 0.77%. The interest for biotechnology companies is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 4.83%.
There is not enough data for artificial intelligence in drug development to provide analysis
There is not enough data for artificial intelligence in drug development to provide correlation calculation
There is not enough data for artificial intelligence in drug development to provide analysis
After 38 days of this quarter the interest is at 193.0. Based on that we can calculate that during remaining 53 days it will total up to 462.0. PARP inhibitors expected interest is significantly higher compared to same quarter last year (+41.3%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 290 | 349 20.3% QoQ | 340 -2.6% QoQ | 328 -3.5% QoQ |
| 2020 | 245 -15.5% YoY -25.3% QoQ | 283 -18.9% YoY 15.5% QoQ | 366 7.6% YoY 29.3% QoQ | 297 -9.5% YoY -18.9% QoQ |
| 2021 | 260 6.1% YoY -12.5% QoQ | 263 -7.1% YoY 1.2% QoQ | 172 -53.0% YoY -34.6% QoQ | 303 2.0% YoY 76.2% QoQ |
| 2022 | 332 27.7% YoY 9.6% QoQ | 246 -6.5% YoY -25.9% QoQ | 185 7.6% YoY -24.8% QoQ | 267 -11.9% YoY 44.3% QoQ |
| 2023 | 327 -1.5% YoY 22.5% QoQ | 254 3.3% YoY -22.3% QoQ | 214 15.7% YoY -15.7% QoQ | 336 25.8% YoY 57.0% QoQ |
| 2024 | 193 -41.0% YoY -42.6% QoQ | - | - | - |
The average 5 years interest of PARP inhibitors was 22.41 per week. The last year interest of PARP inhibitors compared to the last 5 years has changed by 0.4%. The interest for PARP inhibitors is seasonal. The last year interest is quite lower compared to 5 years ago. It has decreased by -16.26%.
After 38 days of this quarter the interest is at 75.0. Based on that we can calculate that during remaining 53 days it will total up to 180.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 189 | 128 -32.3% QoQ | 173 35.2% QoQ | 204 17.9% QoQ |
| 2020 | 82 -56.6% YoY -59.8% QoQ | 91 -28.9% YoY 11.0% QoQ | 151 -12.7% YoY 65.9% QoQ | 189 -7.4% YoY 25.2% QoQ |
| 2021 | 270 229.3% YoY 42.9% QoQ | 0 -100.0% YoY -100.0% QoQ | 215 42.4% YoY inf% QoQ | 103 -45.5% YoY -52.1% QoQ |
| 2022 | 137 -49.3% YoY 33.0% QoQ | 162 inf% YoY 18.2% QoQ | 97 -54.9% YoY -40.1% QoQ | 87 -15.5% YoY -10.3% QoQ |
| 2023 | 172 25.5% YoY 97.7% QoQ | 182 12.3% YoY 5.8% QoQ | 266 174.2% YoY 46.2% QoQ | 224 157.5% YoY -15.8% QoQ |
| 2024 | 75 -56.4% YoY -66.5% QoQ | - | - | - |
The average 5 years interest of non-small cell lung cancer treatment was 12.25 per week. The last year interest of non-small cell lung cancer treatment compared to the last 5 years has changed by 30.78%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 20.0%.
After 38 days of this quarter the interest is at 50.0. Based on that we can calculate that during remaining 53 days it will total up to 120.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 113 | 81 -28.3% QoQ | 89 9.9% QoQ | 163 83.1% QoQ |
| 2020 | 135 19.5% YoY -17.2% QoQ | 111 37.0% YoY -17.8% QoQ | 201 125.8% YoY 81.1% QoQ | 148 -9.2% YoY -26.4% QoQ |
| 2021 | 218 61.5% YoY 47.3% QoQ | 103 -7.2% YoY -52.8% QoQ | 198 -1.5% YoY 92.2% QoQ | 74 -50.0% YoY -62.6% QoQ |
| 2022 | 149 -31.7% YoY 101.4% QoQ | 122 18.4% YoY -18.1% QoQ | 188 -5.1% YoY 54.1% QoQ | 241 225.7% YoY 28.2% QoQ |
| 2023 | 101 -32.2% YoY -58.1% QoQ | 90 -26.2% YoY -10.9% QoQ | 187 -0.5% YoY 107.8% QoQ | 91 -62.2% YoY -51.3% QoQ |
| 2024 | 50 -50.5% YoY -45.1% QoQ | - | - | - |
The average 5 years interest of mantle cell lymphoma treatment was 10.93 per week. The last year interest of mantle cell lymphoma treatment compared to the last 5 years has changed by -8.69%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 3.21%.
There is not enough data for double hit lymphoma treatment to provide analysis
There is not enough data for double hit lymphoma treatment to provide correlation calculation
There is not enough data for double hit lymphoma treatment to provide analysis
There is not enough data for antibody drug conjugate therapeutic approach to provide analysis
There is not enough data for antibody drug conjugate therapeutic approach to provide correlation calculation
There is not enough data for antibody drug conjugate therapeutic approach to provide analysis
There is not enough data for RADR artificial intelligence platform to provide analysis
There is not enough data for RADR artificial intelligence platform to provide correlation calculation
There is not enough data for RADR artificial intelligence platform to provide analysis